Beat-to-beat Evaluation of Atrial Pacing to Test Fluid Responsiveness

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMaastricht University Medical Center

About this trial

The goal of this observational study is to learn whether atrial pacing-induced preload variation can identify fluid responsiveness in adult patients admitted to the intensive care unit after cardiac surgery.

The main questions it aims to answer are:

Can beat-to-beat atrial pacing induce measurable changes in stroke volume that predict fluid responsiveness? Do stroke volume changes measured by transthoracic echocardiography (LVOT VTI) and arterial waveform analysis identify patients who respond to a 500 mL fluid bolus?

Researchers will compare fluid responders and non-responders, defined by a ≥10% increase in stroke volume after a 500 mL Ringer's lactate fluid bolus, to determine whether pacing-induced hemodynamic changes predict fluid responsiveness.

Participants will:

Undergo a standardized atrial pacing protocol (80-120 bpm in 10 bpm increments) before and after a routine 500 mL Ringer's lactate fluid bolus.

Undergo transthoracic echocardiography and continuous arterial pressure monitoring during the pacing protocol.

Have routine ICU hemodynamic data collected during their admission.

Eligibility criteria

Qualifiers

Aged 18 years or older.

Underwent CABG surgery, without concomitant valve surgery.

Admitted to the ICU during the first postoperative day.

Equipped with surgically placed temporary atrial pacemaker wire.

Disqualifiers

Presence of atrial fibrillation or other arrhythmias precluding atrial pacing.

Absence of atrial pacemaker wire.

Suspected cardiac tamponade or significant postoperative bleeding (e.g., >400 mL blood loss in the first hour postoperatively).

Use of extracorporeal life support (ECLS) during the observation period.

Trial design

Treatments tested in this trial

  • Pacing protocol via routinely placed surgical pacemaker wire

Treatment groups

18 Participants
are divided into 1 treatment group

Locations

This trial has no locations